![]() ![]() The following interview has been lightly edited and condensed for clarity.īIOPHARMA DIVE: There's this idea of founder-led biotech, which is sometimes mentioned in contrast to some of the venture capital models that are out there. The company, which now employs about 75 staff, aims to bring its first therapy into clinical testing next year.īioPharma Dive spoke with Becraft about the founder-led biotech movement, the ongoing public market downturn for drugmakers and the appeal of “platform” companies. It’s raised $58 million to date in seed and venture funding, but its investors are from outside the familiar circle of East Coast biotech backers. ![]() “There’s still good science that goes unfunded, and there’s bad science that gets funded,” he said in an interview.īecraft founded Strand in 2017 to build medicines from messenger RNA, years before the strips of genetic code would power the COVID-19 vaccines from Moderna and Pfizer partner BioNTech. ![]() Jake Becraft, the CEO and cofounder of Strand Therapeutics, is one of those advocating for more founder-led biotech companies, as well as for an ecosystem that’s more conducive to funding and supporting their development. But it’s birthed similar companies, too, which can struggle to stand out, some argue. It’s a controlled approach that’s led to high-profile successes like Moderna as well as a host of other well-resourced companies advancing new drugmaking technologies. These firms often form and incubate young drugmakers around ideas developed in-house and equip them with the tools, funding and executives they need to advance their research. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |